Evidence supporting the use of: DL-phenylalanine
For the health condition: Addictions (drugs)

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 1

DL-Phenylalanine (DLPA) has been investigated as a potential adjunct in the treatment of addictions, especially for substances such as alcohol and opioids. The rationale stems from its role as a precursor to neurotransmitters like dopamine, norepinephrine, and endorphins, which are involved in reward pathways linked to addiction. Early studies and some clinical reports from the 1980s suggested that DLPA could reduce withdrawal symptoms and cravings, potentially by boosting endorphin levels or modulating dopamine function. However, the scientific evidence is limited and of low quality: most studies are small, uncontrolled, or dated, and systematic reviews do not support DLPA as an evidence-based treatment for addiction. Major guidelines for addiction treatment do not recommend its use. While there is a plausible biochemical mechanism, robust clinical trials demonstrating efficacy and safety are lacking, and most support comes from preliminary research or anecdotal reports. Thus, while DLPA has been considered for addiction support in some alternative medicine circles based on its neurochemical properties, its use is not well validated by current scientific standards.

More about DL-phenylalanine
More about Addictions (drugs)

Products containing DL-phenylalanine

We currently have no products on Vitabase that contain this ingredient.